Celltrion Presentations & Investor Relations material

• Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development (R&D) capabilities in biosimilar monoclonal antibodies (mAbs) and novel drugs for various therapeutic areas, including oncology and autoimmune diseases. Celltrion previously received EMA approval for Remsima® which is the world's first biosimilar mAb to receive approval from a regulatory agency in a developed country. Celltrion's R&D expertise, coupled with a passion for patient well-being, is a unique set of capabilities that allowed the Company to enter into this highly challenging space.